Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome

NCT07927283 is registered in ClinicalTrials.gov with Arizona State University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07927283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Fulvic Acid Supplementation for the Attenuation of Symptoms Associated With Metabolic Syndrome
Lead sponsor
Arizona State University
Phase
Not applicable
Overall status
Recruiting
Start date
November 6, 2026
Completion date
November 15, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 3 arms.

  • Fulvic acid 50 Experimentalfulvic acid

    50 mg

  • Fulvic acid 100 Experimentalfulvic acid

    100 mg

  • Placebo Placebo comparatorPlacebo

    cornstarch

Primary endpoints

Registered primary outcome measures; 5 primary.

  • girth from enrollment to 6 week and to 12 week

    waist circumference in cm

  • hypertension from enrollment to 6 week and to 12 week

    diastolic and systolic blood pressure

  • hyperglycemia from enrollment to 6 week and to 12 week

    fasting blood glucose

  • hypertriglyceridemia from enrollment to 6 week and to 12 week

    fasting blood triglycerides

  • cholesterol from enrollment to 6 week and to 12 week

    fasting blood HDL cholesterol

Lead sponsor's other trials

Arizona State University, most recent start first.

Similar trials

Same condition (Glucose Intolerance) and phase, most recent start first.